welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
study id #: NCT03362502
condition: Duchenne Muscular Dystrophy
status: active, not recruiting
purpose:This is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non-ambulatory subjects with Duchenne muscular dystrophy (DMD). Other objectives include measurement of dystrophin expression and distribution, and assessments of muscle strength, quality, and function.
A total of approximately 30 subjects will receive PF-06939926, and these will include both ambulatory and non-ambulatory subjects. In order to mitigate unanticipated risks to subject safety, enrollment will be staggered within and between two planned dose-levels and will include a formal review by an external data monitoring committee (E-DMC) prior to dose progression.
intervention: PF-06939926
mechanism of action: Gene therapy to introduce a version of dystrophin
results: https://clinicaltrials.gov/ct2/show/results/NCT03362502
last updated: October 21, 2020
rareRelated
-
RotM: Interview with Prof. Steve WinderFor our recent Researcher of the Month, ...
-
Preliminary Data and Intention to Dose Escalate in IGNITE DMDToday we announced our intention to move...
-
UCLA research could be first step toward healing the hearts of children with DuchenneAfter a progressive weakening of the mus...
-
SGT-001 improves muscle function of dogs with Duchenne muscular dystrophy, studies showSolid Biosciences’ SGT-001 improved mu...
-
NIH Awards $86 Million to Improve Genome Editing TechniquesSomatic Cell Genome Editing support is a...
-
Gene Therapy as a Potential Therapeutic Option for Duchenne Muscular Dystrophy: A Qualitative Preference Study of Pa...Objectives: Duchenne muscular dystrophy...
-
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exon...CureDuchenne, a nonprofit global leader ...